ANXA5 and cancer: The ability of cancer cell lines to clot plasma is abrogated by incubating with a TF-blocking antibody, or with Annexin V, which blocks the binding of coagulation factors to the PS-containing cancer cell membrane (Berny-Lang et al., 2011).